Latest Conference Articles

January 20th 2018, 3:52am

Gastrointestinal Cancers Symposium (ASCO GI)

Tanios Bekaii-Saab, MD, discusses the results and significance of the ReDOS study in metastatic colorectal cancer, as well as shared some insight on the Reverce trial.

January 20th 2018, 3:18am

Gastrointestinal Cancers Symposium (ASCO GI)

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study of entrectinib in patients with pancreas cancer.

January 20th 2018, 3:18am

Gastrointestinal Cancers Symposium (ASCO GI)

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, Univeristy of Chicago Medicine, discusses margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) as treatment for patients with advanced HER2-positive gastroesophageal junction (GEJ) or gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

January 20th 2018, 3:01am

Gastrointestinal Cancers Symposium (ASCO GI)

The CellMax biomimetic platform, a novel circulating tumor cell assay, was 84% to 88% accurate at detecting precancerous and cancerous colorectal lesions.

January 19th 2018, 11:29pm

Gastrointestinal Cancers Symposium (ASCO GI)

Nivolumab alone and in combination with ipilimumab induced responses in patients with heavily pretreated gastrointestinal stromal tumor.

January 19th 2018, 10:03pm

Gastrointestinal Cancers Symposium (ASCO GI)

Adding ramucirumab to standard first-line chemotherapy significantly improved investigator-assessed progression-free survival compared with chemotherapy plus placebo in treatment-naive patients with HER2-negative gastric cancer.

January 19th 2018, 8:08am

Gastrointestinal Cancers Symposium (ASCO GI)

Maria Svensson, MD, Lund University, discusses the associations of PD-1 and PD-L1 expression with mismatch repair (MMR) status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

January 19th 2018, 8:07am

Gastrointestinal Cancers Symposium (ASCO GI)

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses a phase II study of nivolumab (Opdivo) in patients with metastatic unresectable gastrointestinal stromal tumors (GIST) during the 2018 Gastrointestinal Cancers Symposium.

January 19th 2018, 4:08am

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of the VEGFR-2 inhibitor ramucirumab plus the anti-PD-L1 agent durvalumab demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

January 19th 2018, 3:58am

Gastrointestinal Cancers Symposium (ASCO GI)

The novel investigational HER2-targeting antibody-drug conjugate trastuzumab deruxtecan showed promising antitumor activity in heavily pretreated patients with HER2-expressing gastric cancer.

January 17th 2018, 3:37am

Gastrointestinal Cancers Symposium (ASCO GI)

Treatment with cabozantinib improved median overall survival by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma.

December 14th 2017, 1:14am

ASH Annual Meeting and Exposition

The addition of carfilzomib to lenalidomide and dexamethasone for relapsed/refractory multiple myeloma led to a statistically significant 21% reduction in the risk for death compared with lenalidomide and dexamethasone.

December 13th 2017, 7:51pm

ASH Annual Meeting and Exposition

The B-cell maturation antigen antibody-drug conjugate GSK2857916 induced an overall response rate of 60% in heavily pretreated patients with multiple myeloma.

December 13th 2017, 7:11pm

ASH Annual Meeting and Exposition

Maintenance therapy with elotuzumab (Empliciti) and lenalidomide (Revlimid) after autologous stem cell transplant improves the quality of response achieved with induction therapy in patients with multiple myeloma.

December 13th 2017, 7:00am

ASH Annual Meeting and Exposition

The IDH1 inhibitor ivosidenib induced a complete response (CR) or CR with partial hematologic recovery for 30.4% of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.

December 13th 2017, 3:25am

ASH Annual Meeting and Exposition

Patients with cancer who have venous thromboembolism had similar rates of recurrent VTE or bleeding with the oral factor Xa inhibitor edoxaban (Savaysa) or the low-molecular weight heparin dalteparin (Fragmin).

December 13th 2017, 2:02am

ASH Annual Meeting and Exposition

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.

December 13th 2017, 1:51am

ASH Annual Meeting and Exposition

Daratumumab (Darzalex) displayed single-agent activity in intermediate- and high-risk smoldering multiple myeloma, according to results from the phase II CENTAURUS study.

December 12th 2017, 10:12pm

ASH Annual Meeting and Exposition

Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting. Overall, 32 patients were treated with this combination in the first-line setting. Investigators saw high complete remission (CR) rates, with over two-thirds of patients experiencing a CR, Flinn explains. In addition, high MRD negativity rates were also demonstrated, in both the peripheral blood and the bone marrow.

December 12th 2017, 8:54pm

ASH Annual Meeting and Exposition

The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) reduced the risk of progression or death by 50% compared with VMP alone for transplant-ineligible patients with newly diagnosed multiple myeloma.